PRESS RELEASE view as PDF

For More Information:

SAMDI Tech, Inc.
Lisa Sanford
Senior Director of Business Development
Phone: +1 914 384 2137
email

Exquiron Biotech AG
Stephan Fasler
CEO
Phone: +41 61 716 85 85
sfasler@exquiron.com

SAMDI Tech, Inc and Exquiron Announce Partnership Agreement

CHICAGO, IL – February 8, 2015 -- SAMDI Tech and Exquiron are expanding their service offering by entering into a partnership agreement, allowing SAMDI Tech and Exquiron to mutually promote their respective services in Europe and North America. The two companies aim to offer hit discovery, hit profiling, and assay development services, combining their expertise to the benefit of their clients. The partnership provides SAMDI Tech’s clients the added benefit of Exquiron’s broad assay capabilities and lead-like, 250,000 compound collection as well as access of SAMDI Tech’s exclusive label-free, MALDI-TOF capabilities to Exquiron and its clients.

“I am excited to partner with Exquiron as our technology is innovative to the discovery field and coupled with Exquiron’s additional assay capabilities and compound collection we can offer a comprehensive solution to our clients.” said Emilio Córdova Ph.D., MBA, CEO at SAMDI Tech.

SAMDI is a unique label-free assay platform for measurement of complex biochemical activity.

Stephan Fasler Ph.D., CEO of Exquiron commented “We have previously collaborated with SAMDI Tech; the company has been our first choice for entering into this partnership. We are impressed by the novelty and quality of SAMDI Tech’s label-free assay technology, which, coupled with their excellent assay development services, renders SAMDI Tech a company to absolutely work with.”

About SAMDI Tech, Inc
SAMDI Tech, Inc, headquartered in Chicago, IL is a contract research organization supporting discovery research. SAMDI’s pioneering technology combines surface chemistry and MALDI mass spectrometry in both 384 and 1536 format for rapid assay development, high-throughput screening, and peptide substrate discovery and supports both biotech and large pharmaceutical companies. Learn more about SAMDI Tech at www.samditech.com.

About Exquiron Biotech AG
Exquiron, headquartered in Reinach BL, Switzerland, is a company dedicated to contract research in early stage drug discovery. Its services span from assay development for hit finding and profiling purposes to compound selection, high throughput screening, selectivity testing and hit characterization, and SAR expansion. Exquiron’s team brings extensive skills and know-how in all areas of the hit identification process, including broad target class coverage, applicable technologies, data processing and evaluation. Learn more about Exquiron at www.exquiron.com.

#####